Study guide
5.2 Chronic Kidney Disease & Renal Replacement Therapy
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
5.2 Chronic Kidney Disease & Renal Replacement Therapy
Key Takeaways Explain This Topic AI
Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function present for >3 months, staged by eGFR (G1-G5) and Albuminuria categories (A1 <3 mg/mmol, A2 3-30 mg/mmol, A3 >30 mg/mmol).
SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) reduce intraglomerular pressure by restoring tubuloglomerular feedback, slowing CKD progression and reducing cardiovascular mortality in patients with eGFR ≥20 mL/min/1.73m².
CKD-Mineral and Bone Disorder (CKD-MBD) develops from hyperphosphatemia, impaired 1-α-hydroxylation of vitamin D (low active 1,25-(OH)2D3), hypocalcemia, and compensatory secondary hyperparathyroidism.
Anemia of CKD is predominantly due to deficient renal erythropoietin production by peritubular interstitial cells, managed with erythropoiesis-stimulating agents (ESAs) to maintain hemoglobin at 100-115 g/L once iron stores are replete (ferritin >100 μg/L, TSAT >20%).
Absolute emergency indications for renal replacement therapy (RRT) follow the AEIOU mnemonic: refractory Acidosis (pH <7.15), refractory Hyperkalemia (>6.5 mmol/L), Intoxication (SLIME), Fluid Overload, and Uremic complications (pericarditis, encephalopathy).
Last updated: July 2026
Chronic Kidney Disease & Renal Replacement Therapy
Chronic Kidney Disease (CKD) is defined by KDIGO guidelines as abnormalities of kidney structure or function, present for > 3 > 3 > 3 months , with implications for health. It affects over 10% of the global adult population and represents a potent independent risk factor for cardiovascular events, heart failure, and all-cause mortality.
KDIGO Staging & Classification System
CKD classification utilizes a two-dimensional grid based on eGFR (G-stage) and Albuminuria (A-stage) , which together predict the risks of progression, cardiovascular events, and mortality.
- eGFR Category eGFR Range ( mL/min/1.73m 2 \text{mL/min/1.73m}^2 mL/min/1.73m 2 ) Clinical Description
- G1 ≥ 90 \ge 90 ≥ 90 Normal or high (requires structural/histological evidence of kidney damage)
- G2 60 – 89 60\text{--}89 60 – 89 Mildly decreased (requires structural/histological evidence of kidney damage)
- G3a 45 – 59 45\text{--}59 45 – 59 Mildly to moderately decreased
- G3b 30 – 44 30\text{--}44 30 – 44 Moderately to severely decreased
- G4 15 – 29 15\text{--}29 15 – 29 Severely decreased
- G5 < 15 < 15 < 15 Kidney failure (End-Stage Renal Disease / ESRD)
Albuminuria Category ACR Range ( mg/mmol \text{mg/mmol} mg/mmol ) ACR Range ( mg/g \text{mg/g} mg/g ) Clinical Description
A1 < 3.0 < 3.0 < 3.0 < 30 < 30 < 30 Normal to mildly increased
A2 3.0 – 30.0 3.0\text{--}30.0 3.0 – 30.0 30 – 300 30\text{--}300 30 – 300 Moderately increased (microalbuminuria)
- A3 > 30.0 > 30.0 > 30.0 > 300 > 300 > 300 Severely increased (macroalbuminuria)
- Disease-Modifying Pharmacotherapy in CKD
The goal of CKD management is to slow disease progression, reduce albuminuria, and minimize cardiovascular risk.
1. Renin-Angiotensin-Aldosterone System (RAAS) Inhibition
Agents : ACE inhibitors (e.g., ramipril, enalapril) or Angiotensin Receptor Blockers (ARBs, e.g., losartan, valsartan).
Mechanism : Preferentially dilate the efferent arteriole of the glomerulus, reducing intraglomerular hydrostatic pressure and glomerular hyperfiltration.
Monitoring : Expect an initial serum creatinine rise up to 30 % 30\% 30% within 4 weeks of initiation; this reflects hemodynamic pressure reduction and does not warrant drug cessation unless creatinine continues to rise or refractory hyperkalemia occurs.
2. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Agents : Dapagliflozin, empagliflozin, canagliflozin.
Mechanism : Block glucose and sodium reabsorption in the proximal convoluted tubule. Increased sodium delivery to the macula densa restores tubuloglomerular feedback , inducing afferent arteriolar constriction and reducing intraglomerular hypertension.
Clinical Evidence : Landmark trials (DAPA-CKD, EMPA-KIDNEY) demonstrate significant reductions in CKD progression, kidney failure, cardiovascular death, and heart failure hospitalizations down to an eGFR of 20 mL/min/1.73m 2 20\,\text{mL/min/1.73m}^2 20 mL/min/1.73m 2 .
3. Non-Steroidal Mineralocorticoid Receptor Antagonists
Finerenone : Demonstrates additive antiproteinuric and cardiorenal protective benefits in patients with type 2 diabetes and CKD already taking maximum tolerated doses of ACEi/ARB and SGLT2 inhibitors.
- Management of Systemic CKD Complications
- 1. CKD-Mineral and Bone Disorder (CKD-MBD)
As eGFR declines below 45 mL/min/1.73m 2 45\,\text{mL/min/1.73m}^2 45 mL/min/1.73m 2 , phosphorus excretion drops, leading to hyperphosphatemia. Concurrently, renal peritubular cells fail to produce 1 - α -hydroxylase 1\text{-}\alpha\text{-hydroxylase} 1 - α -hydroxylase , resulting in calcitriol ( 1 , 25 ( OH ) 2 D 3 1,25(\text{OH})_2\text{D}_3 1 , 25 ( OH ) 2 D 3 ) deficiency.
Pathophysiology Pathway :
Decreased eGFR ( < 45 mL/min <45\,\text{mL/min} < 45 mL/min ) → \rightarrow → Phosphate retention → \rightarrow → Hyperphosphatemia
Reduced 1 - α -hydroxylase 1\text{-}\alpha\text{-hydroxylase} 1 - α -hydroxylase → \rightarrow → Low 1 , 25 ( OH ) 2 D 3 1,25(\text{OH})_2\text{D}_3 1 , 25 ( OH ) 2 D 3 → \rightarrow → Reduced intestinal Ca 2 + \text{Ca}^{2+} Ca 2 + absorption → \rightarrow → Hypocalcemia
Hypocalcemia + Hyperphosphatemia + Low Calcitriol → \rightarrow → Secondary Hyperparathyroidism (High PTH) → \rightarrow → Bone resorption (Osteitis Fibrosa Cystica)
Management :
Dietary Phosphate Restriction : Limit dairy, nuts, processed foods.
Phosphate Binders : Non-calcium-based binders ( Sevelamer , Lanthanum) are preferred over calcium-based binders (calcium acetate, calcium carbonate) to avoid accelerating vascular calcification.
Active Vitamin D Analogs : Alfacalcidol or Calcitriol (native vitamin D / cholecalciferol cannot be hydroxylated by the kidney in advanced CKD).
Calcimimetics : Cinacalcet activates calcium-sensing receptors on the parathyroid gland, suppressing PTH secretion without causing hypercalcemia.
2. Anemia of Chronic Kidney Disease
Pathophysiology : Deficient production of erythropoietin (EPO) by peritubular interstitial cells of the renal cortex. Additional factors include hepcidin-mediated iron sequestration, uremic toxins reducing RBC lifespan, and frequent blood loss.
Diagnostic Target : Normocytic, normochromic anemia. Iron stores must be evaluated prior to Erythropoiesis-Stimulating Agent (ESA) therapy:
Serum Ferritin : Target > 100 μ g/L > 100\,\mu\text{g/L} > 100 μ g/L ( > 200 μ g/L > 200\,\mu\text{g/L} > 200 μ g/L in hemodialysis).
Transferrin Saturation (TSAT) : Target > 20 % > 20\% > 20% .
ESA Therapy : Epoetin alfa/beta or Darbepoetin alfa. Target hemoglobin level is 100 – 115 g/L 100\text{--}115\,\text{g/L} 100 – 115 g/L .
Exam Pearl: Normalizing hemoglobin to > 120 g/L > 120\,\text{g/L} > 120 g/L with ESAs increases the risk of stroke, myocardial infarction, arteriovenous access thrombosis, and hypertension without conferring quality-of-life benefit.
Renal Replacement Therapy (RRT)
When eGFR drops below 15 mL/min/1.73m 2 15\,\text{mL/min/1.73m}^2 15 mL/min/1.73m 2 (G5), patients require planning for RRT.
Absolute Indications for Emergency RRT (The "AEIOU" Mnemonic)
A cidosis: Severe metabolic acidosis ( pH < 7.15 \text{pH} < 7.15 pH < 7.15 ) refractory to medical management (e.g., sodium bicarbonate).
E lectrolytes: Severe hyperkalemia ( [ K + ] > 6.5 mmol/L [\text{K}^+] > 6.5\,\text{mmol/L} [ K + ] > 6.5 mmol/L ) refractory to intravenous insulin-dextrose and potassium binders.
I ntoxication: Poisoning with dialyzable toxins ( SLIME : Salicylates, Lithium, Isopropanol, Methanol, Ethylene glycol).
O verload: Refractory volume overload / acute pulmonary edema resistant to high-dose loop diuretics.
U remia: Uremic encephalopathy, uremic pericarditis (pericardial rub), uremic neuropathy, or uremic bleeding.
Dialysis Modalities Comparison
Feature Hemodialysis (HD) Peritoneal Dialysis (PD)
Access Arteriovenous (AV) fistula (preferred), AV graft, or central venous catheter Permanent Tenckhoff peritoneal catheter
Mechanism Solute diffusion and ultrafiltration across semipermeable synthetic membrane Peritoneal membrane acts as natural semipermeable membrane; dextrose dialysate
Schedule Thrice weekly (4 hours per session in center) Daily (CAPD: 4 manual exchanges/day; APD: overnight machine)
Primary Complication Vascular access thrombosis/infection, dialysis disequilibrium syndrome, β 2 \beta_2 β 2 -microglobulin amyloidosis Peritonitis ( Staph epidermidis , Staph aureus , Gram-negative bacilli; cloudy dialysate, WBC > 100 / μ L \text{WBC} > 100/\mu\text{L} WBC > 100/ μ L with > 50 % > 50\% > 50% PMNs)
Kidney Transplantation
Kidney transplantation is the treatment of choice for ESRD, offering superior survival and quality of life compared to maintenance dialysis.
Immunosuppression Regimens : Triple therapy consisting of a Calcineurin Inhibitor (Tacrolimus or Cyclosporine), an Antimetabolite (Mycophenolate Mofetil or Azathioprine), and Corticosteroids (Prednisolone).
Calcineurin Inhibitor Toxicity : Causes afferent arteriolar vasoconstriction, presenting with hypertension, tremor, hypomagnesemia, hyperkalemia, and dose-dependent nephrotoxicity (striped interstitial fibrosis on biopsy).